- Home
- UNCY vs NSPR Comparison
UNCY vs NSPR Comparison
Compare UNCY & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- NSPR
- Stock Information
- Founded
- UNCY 2016
- NSPR 2005
- Country
- UNCY United States
- NSPR Israel
- Employees
- UNCY N/A
- NSPR N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- UNCY Health Care
- NSPR Health Care
- Exchange
- UNCY Nasdaq
- NSPR Nasdaq
- Market Cap
- UNCY 70.3M
- NSPR 63.0M
- IPO Year
- UNCY 2021
- NSPR N/A
- Fundamental
- Price
- UNCY $0.62
- NSPR $2.72
- Analyst Decision
- UNCY Strong Buy
- NSPR Strong Buy
- Analyst Count
- UNCY 4
- NSPR 2
- Target Price
- UNCY $5.50
- NSPR $4.75
- AVG Volume (30 Days)
- UNCY 1.3M
- NSPR 27.8K
- Earning Date
- UNCY 11-13-2024
- NSPR 03-05-2025
- Dividend Yield
- UNCY N/A
- NSPR N/A
- EPS Growth
- UNCY N/A
- NSPR N/A
- EPS
- UNCY N/A
- NSPR N/A
- Revenue
- UNCY N/A
- NSPR $6,821,000.00
- Revenue This Year
- UNCY N/A
- NSPR $13.36
- Revenue Next Year
- UNCY N/A
- NSPR $49.64
- P/E Ratio
- UNCY N/A
- NSPR N/A
- Revenue Growth
- UNCY N/A
- NSPR 24.70
- 52 Week Low
- UNCY $0.20
- NSPR $1.81
- 52 Week High
- UNCY $1.82
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- UNCY 40.04
- NSPR 47.01
- Support Level
- UNCY $0.61
- NSPR $2.50
- Resistance Level
- UNCY $0.73
- NSPR $2.83
- Average True Range (ATR)
- UNCY 0.07
- NSPR 0.20
- MACD
- UNCY -0.02
- NSPR -0.01
- Stochastic Oscillator
- UNCY 15.66
- NSPR 41.54
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.